{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:13Z","timestamp":1791903313348,"version":"4.3.4"},"reference-count":33,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The use of nonfactor products such as emicizumab, a bispecific antibody that mimics the cofactor function of activated factor VIII (FVIIIa) by bridging FIXa and FX, has significantly reduced bleeding episodes in people with hemophilia A (HA). However, emicizumab high species specificity in its FVIIIa-mimetic cofactor activity has limited in vivo functional evaluation to an acquired HA nonhuman primate model or congenital HA mouse model with infusion of human FIX (hFIX) and hFX proteins. To overcome the limitations of existing models, we generated hFIX\/hFX double-knockin congenital HA model (humanized HA [HuHA]) mice. HuHA mice were established by the replacement of mouse FIX\/FX genes with their human homologs and by the disruption of mouse FVIII. In HuHA mice, functional hFIX and hFX are constitutively expressed at levels equivalent to, or higher than, human plasma concentrations. Thrombin generation assays demonstrated dose dependently improved peak thrombin generation by both recombinant hFVIII (rhFVIII) and emicizumab. These HuHA mice were found to express sufficient levels of hFIX and hFX to support functional evaluation of rhFVIII and emicizumab activities. Furthermore, the tail-clip assay suggested potential hemostatic effects of both therapeutic agents in vivo, although the findings should be interpreted with caution given the limitations of the model. This novel mouse model, in which functional hFIX and hFX are constitutively expressed on an FVIII-deficient background, may provide a new platform for the preclinical evaluation of human-specific therapeutics for HA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018528","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:01:02Z","timestamp":1781204462000},"page":"6685-6693","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["A novel humanized FIX\/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5444-9709","authenticated-orcid":false,"given":"Tomoyuki","family":"Watanabe","sequence":"first","affiliation":[{"name":"1Chugai Pharmaceutical Co, Ltd, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7144-001X","authenticated-orcid":false,"given":"Asuka","family":"Sakata","sequence":"additional","affiliation":[{"name":"2Medicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-596X","authenticated-orcid":false,"given":"Naoki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"1Chugai Pharmaceutical Co, Ltd, Yokohama, Japan"},{"name":"2Medicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Harada","sequence":"additional","affiliation":[{"name":"1Chugai Pharmaceutical Co, Ltd, Yokohama, Japan"},{"name":"2Medicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"1Chugai Pharmaceutical Co, Ltd, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otoya","family":"Ueda","sequence":"additional","affiliation":[{"name":"1Chugai Pharmaceutical Co, Ltd, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Soeda","sequence":"additional","affiliation":[{"name":"1Chugai Pharmaceutical Co, Ltd, Yokohama, Japan"},{"name":"2Medicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tatsumi","sequence":"additional","affiliation":[{"name":"2Medicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan"},{"name":"3Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[{"name":"2Medicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"2Medicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan"},{"name":"4Department of Pediatrics, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"4","key":"2026101310424372700_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5435\/00124635-200407000-00004","article-title":"Hemophilic arthropathy","volume":"12","author":"Luck","year":"2004","journal-title":"J Am Acad Orthop Surg"},{"issue":"10274","key":"2026101310424372700_bib2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"2026101310424372700_bib3","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2026101310424372700_bib4","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"2026101310424372700_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2026101310424372700_bib6","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"16","key":"2026101310424372700_bib7","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026101310424372700_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"2026101310424372700_bib9","doi-asserted-by":"crossref","first-page":"e12670","DOI":"10.1002\/rth2.12670","article-title":"Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2026101310424372700_bib10","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"Negrier","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"2026101310424372700_bib11","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026101310424372700_bib12","doi-asserted-by":"crossref","first-page":"e12837","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jimenez-Yuste","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2026101310424372700_bib13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"2026101310424372700_bib14","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.rpth.2025.102717","article-title":"Real-world bleeding rates on emicizumab: the value of using nationwide digital treatment diary data in clinical research","volume":"9","author":"Brands","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 4","key":"2026101310424372700_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14524","article-title":"Emicizumab state-of-the-art update","volume":"28","author":"Mahlangu","year":"2022","journal-title":"Haemophilia"},{"issue":"10","key":"2026101310424372700_bib16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"2026101310424372700_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026101310424372700_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet"},{"issue":"2","key":"2026101310424372700_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jth.13202","article-title":"Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene","volume":"14","author":"Chao","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2026101310424372700_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12959-016-0106-0","article-title":"Current animal models of hemophilia: the state of the art","volume":"14","author":"Yen","year":"2016","journal-title":"Thromb J"},{"issue":"6","key":"2026101310424372700_bib21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"Ferriere","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026101310424372700_bib22","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/j.1538-7836.2012.04906.x","article-title":"APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent","volume":"10","author":"Kumano","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026101310424372700_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1021\/bi00507a028","article-title":"Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside","volume":"20","author":"Mimms","year":"1981","journal-title":"Biochemistry"},{"issue":"10","key":"2026101310424372700_bib24","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/j.1538-7836.2007.02719.x","article-title":"Development of a calibrated automated thrombography based thrombin generation test in mouse plasma","volume":"5","author":"Tchaikovski","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026101310424372700_bib25","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/s41598-017-04625-5","article-title":"CRISPR\/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice","volume":"7","author":"Ohmori","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"2026101310424372700_bib26","doi-asserted-by":"crossref","first-page":"e83280","DOI":"10.1371\/journal.pone.0083280","article-title":"A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A","volume":"8","author":"Tatsumi","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2026101310424372700_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s42003-025-07838-x","article-title":"Extravascular coagulation regulates haemostasis independently of activated platelet surfaces in an in vivo mouse model","volume":"8","author":"Sakata","year":"2025","journal-title":"Commun Biol"},{"issue":"24","key":"2026101310424372700_bib28","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood-2014-02-555151","article-title":"A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII","volume":"123","author":"Fahs","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026101310424372700_bib29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.hoc.2021.07.008","article-title":"Hemophilia B (factor IX deficiency)","volume":"35","author":"Sidonio","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"2026101310424372700_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11239-021-02456-w","article-title":"Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics","volume":"52","author":"Camire","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"suppl 1","key":"2026101310424372700_bib32","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2018-99-119012","article-title":"A novel humanized hemophilia-a mouse model to facilitate preclinical in vivo studies of human specific Fviiia-mimetic bispecific antibodies","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2026101310424372700_bib33","doi-asserted-by":"crossref","first-page":"e0145019","DOI":"10.1371\/journal.pone.0145019","article-title":"The influence of SV40 polyA on gene expression of baculovirus expression vector systems","volume":"10","author":"Salem","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"2026101310424372700_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/a-2315-8199","article-title":"Additional factor X enhances emicizumab-driven coagulation function in patients with hemophilia A and hemophilia A mice","volume":"125","author":"Shimizu","year":"2025","journal-title":"Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6685\/2592926\/blooda_adv-2025-018528-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6685\/2592926\/blooda_adv-2025-018528-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:42:50Z","timestamp":1791902570000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6685\/569102\/A-novel-humanized-FIX-FX-hemophilia-A-mouse-model"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":33,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018528","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,30]]}}}